What Are Biosimilars? A Simple Guide for Patients

Have you ever been told your doctor is switching your medication to something called a biosimilar? Maybe you’re worried it’s a cheaper, less reliable version of what you’ve been taking. You’re not alone. Many patients feel confused when they hear this term. But here’s the truth: biosimilars aren’t generic drugs. And they’re not experimental. They’re carefully tested, FDA-approved versions of complex biologic medicines - and they work just like the originals.

What’s a biologic drug anyway?

Before we talk about biosimilars, you need to know what biologics are. These aren’t the little pills you swallow. Biologics are made from living cells - human, animal, or even microbe cells - and they’re huge, complicated molecules. Think of them like a snowflake: no two are exactly alike, even if they’re made the same way. They’re used to treat serious conditions like rheumatoid arthritis, Crohn’s disease, psoriasis, cancer, and diabetes. Examples include Humira, Enbrel, and Herceptin.

Because they’re made from living systems, not chemicals, you can’t just copy them like you would a regular pill. A small-molecule drug like aspirin has one specific chemical structure. A biologic? It’s made of hundreds or thousands of amino acids, folded in precise ways, with sugar molecules attached. Even tiny changes in the manufacturing process - like using a different type of cell or changing the temperature during production - can affect how the drug works. That’s why making a copy isn’t simple.

What exactly is a biosimilar?

A biosimilar is a biologic drug that is highly similar to an already approved biologic - called the reference product. It’s not an exact copy. But it doesn’t need to be. The FDA requires that a biosimilar has no clinically meaningful differences from the original. That means:

• It works the same way in the body
• It treats the same conditions
• It has the same dose, strength, and way of giving it (injection, IV, etc.)
• It has the same safety profile - same side effects, same risks

To get approved, a biosimilar goes through years of testing. Scientists compare it to the original drug at the molecular level, run animal studies, and often do clinical trials with hundreds of patients. For example, the biosimilar Renflexis was tested in 541 patients with rheumatoid arthritis before approval. No surprises. No hidden risks.

The first biosimilar approved in the U.S. was Zarxio in 2015 - a copy of Neupogen, used to help cancer patients recover from chemotherapy. Since then, 41 biosimilars have been approved, with 32 available for use. And they’re not just for rare diseases. They’re now used for common conditions like arthritis, diabetes, and even eye disease.

Biosimilar vs generic: what’s the difference?

This is where things get mixed up. People think biosimilars are like generics. They’re not.

Generics are exact chemical copies of small-molecule drugs. Take ibuprofen. The brand name is Advil. The generic is just ibuprofen. Same molecule. Same atoms. Same everything. You can make it in a lab with chemicals, and it’s identical.

Biosimilars? They’re made from living cells. You can’t make an exact copy. Even if two companies use the same instructions, their biosimilars might have tiny differences - like slightly different sugar attachments. But here’s the key: those differences don’t affect how the drug works in your body. That’s why the FDA calls them “highly similar,” not “identical.”

Think of it like two handmade wooden chairs. They’re built from the same design, same wood, same tools. One might have a slightly different finish. But both hold you up the same way. That’s a biosimilar.

Are biosimilars safe?

Yes. And the data backs it up.

Europe has been using biosimilars for over 15 years. Millions of patients have taken them. No new safety issues have popped up. In the U.S., studies show patients switching from the original biologic to a biosimilar have the same outcomes - same disease control, same side effects, same hospital visits.

The FDA doesn’t approve a biosimilar unless it proves it’s as safe and effective as the original. They monitor every batch. They track every reported side effect. If something unusual happens, they investigate - fast.

Experts from the American Cancer Society, the Arthritis Foundation, and the FDA all say the same thing: approved biosimilars are just as safe as the brand-name biologics.

Will it cost less?

Usually, yes. Biosimilars typically cost 15% to 30% less than the original biologic. That’s not as big a discount as generics (which can be 80% cheaper), but it still adds up. For drugs that cost $20,000 a year, a 20% saving means $4,000 back in your pocket - or your insurance’s.

Some insurance plans now require you to try a biosimilar first before covering the brand-name drug. That’s not because they think it’s inferior - it’s because they know it works just as well and costs less. It’s a way to make care more affordable.

How do you know if you’re getting a biosimilar?

Biosimilars have different names than the original. The generic name is the same, but with a four-letter suffix added. For example:

• Original: infliximab (Remicade)
• Biosimilar: infliximab-dyyb (Renflexis)

This isn’t random. It helps doctors, pharmacists, and insurers track which version you’re taking. If you see a new name on your prescription, don’t panic. It’s just how they’re labeled.

Your doctor will decide if a biosimilar is right for you. But if you’re already stable on a biologic, you can usually stay on it. Switching isn’t required - it’s an option.

What about interchangeable biosimilars?

There’s a special category called “interchangeable” biosimilars. These are approved to be swapped for the original drug without the doctor’s permission - just like generics. The first one approved was Semglee, an insulin glargine biosimilar, in 2021. More are coming. When you see “interchangeable” on the label, it means the FDA has extra confidence that switching back and forth won’t affect your health.

What should you do as a patient?

• Ask your doctor: “Is there a biosimilar option for my treatment?”
• Check with your pharmacist: “Is this a biosimilar?”
• Don’t switch on your own. Always talk to your provider before changing meds.
• Keep taking your medicine as prescribed. Biosimilars aren’t experimental - they’re proven.
• Report any side effects. Your feedback helps keep everyone safe.

Biosimilars aren’t about cutting corners. They’re about giving more people access to life-changing treatments without sacrificing safety. They’ve been tested more than most drugs you’ve ever taken. And they’re helping reduce the cost of care - for you, your family, and the whole system.

If you’ve been on a biologic for years, your body knows how it works. If you switch to a biosimilar, your body won’t notice a difference - because there isn’t one.